Nuvation Bio (NYSE:NUVB) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Nuvation Bio's stock has received a "Sell (D-)" rating from Weiss Ratings, while other analysts have varied opinions with ratings from "Strong Buy" to "Hold."
• The company's stock price decreased by 0.9% to $3.69 amidst a trading volume significantly lower than its average, and it has a market capitalization of $1.26 billion.
• Nuvation Bio reported a quarterly earnings result meeting analysts' expectations, with a revenue of $4.83 million, substantially surpassing estimates of $0.42 million.

Nuvation Bio (NYSE:NUVB - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other analysts also recently issued reports on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $6.00 target price on shares of Nuvation Bio in a research report on Wednesday, June 25th. Wall Street Zen raised Nuvation Bio from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Nuvation Bio in a research report on Friday, September 19th. Jefferies Financial Group assumed coverage on Nuvation Bio in a research report on Tuesday, September 30th. They set a "buy" rating and a $10.00 price target on the stock. Finally, Wedbush reissued an "outperform" rating and set a $6.00 price target on shares of Nuvation Bio in a research report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Nuvation Bio has an average rating of "Moderate Buy" and an average price target of $7.86.

Nuvation Bio Stock Down 0.9%

Shares of Nuvation Bio stock traded down $0.04 during trading on Wednesday, reaching $3.69. The stock had a trading volume of 254,559 shares, compared to its average volume of 4,699,288. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -5.85 and a beta of 1.48. The stock has a fifty day moving average price of $3.03 and a two-hundred day moving average price of $2.42. Nuvation Bio has a 52 week low of $1.54 and a 52 week high of $4.09. The company has a current ratio of 9.39, a quick ratio of 9.38 and a debt-to-equity ratio of 0.13.

Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17). The company had revenue of $4.83 million for the quarter, compared to analyst estimates of $0.42 million. Nuvation Bio had a negative return on equity of 46.14% and a negative net margin of 1,413.43%. Sell-side analysts predict that Nuvation Bio will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Nuvation Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in NUVB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Nuvation Bio by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company's stock worth $191,000 after buying an additional 4,608 shares in the last quarter. Meridian Wealth Management LLC increased its holdings in Nuvation Bio by 5.8% in the second quarter. Meridian Wealth Management LLC now owns 87,115 shares of the company's stock valued at $170,000 after purchasing an additional 4,780 shares during the period. Cresset Asset Management LLC increased its holdings in Nuvation Bio by 3.5% in the second quarter. Cresset Asset Management LLC now owns 143,690 shares of the company's stock valued at $280,000 after purchasing an additional 4,874 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in Nuvation Bio by 20.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 36,486 shares of the company's stock valued at $71,000 after purchasing an additional 6,307 shares during the period. Finally, Exchange Traded Concepts LLC increased its holdings in Nuvation Bio by 11.7% in the first quarter. Exchange Traded Concepts LLC now owns 60,951 shares of the company's stock valued at $107,000 after purchasing an additional 6,403 shares during the period. 61.67% of the stock is currently owned by institutional investors.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.